DHEA for postmenopausal women: A review of the evidence

Maturitas

Volumn 66, Issue 2, 2010, Pages 172-179

  Panjari, Mary ^a   Davis, Susan R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Androgen therapy; DHEA DHEAS; Menopause; Sexual function

Indexed keywords

ANDROGEN; PLACEBO; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ADRENERGIC SYSTEM; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; MENOPAUSAL SYNDROME; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; VAGINA ATROPHY; WELLBEING;

CARBOHYDRATE METABOLISM; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; LIPID METABOLISM; POSTMENOPAUSE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 77952742640     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.12.017     Document Type: Review

References (95)

1. Labrie F., Luu-The V., Belanger A., et al. Is dehydroepiandrosterone a hormone?. J Endocrinol 187 (2005) 169-196
2. Labrie F. Intracrinology. Mol Cell Endocrinol 78 (1991) C113-C118
3. Labrie F., Luu-The V., Labrie C., et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Rev 24 (2003) 152
4. Davis S. Androgens and female sexuality. J Gerontol B Psychol Sci Soc Sci 3 (2000) 32-40
5. Mushayandebvu T., Castracane D.V., Gimpel T., Adel T., and Santoro N. Evidence for diminished midcycle ovarian androgen production in older reproductive aged women. Fertil Steril 65 (1996) 721
6. Davison S.L., Bell R., Donath S., Montalto J.G., and Davis S.R. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90 (2005) 3847-3853
7. Fogle R.H., Stanczyk F.Z., Zhang X., and Paulson R.J. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 92 (2007) 3040-3043
8. Labrie F. Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol (Paris) 64 (2003) 95-107
9. Labrie F. Adrenal androgens and intracrinology [see comment]. Semin Reprod Med 22 (2004) 299-309
10. Labrie F. DHEA as physiological replacement therapy at menopause [see comment]. J Endocrinol Invest 21 (1998) 399-401
11. Auchus R.J. Overview of dehydroepiandrosterone biosynthesis. Semin Reprod Med 22 (2004) 281-288
12. Payne A.H., and Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocrine Rev 25 (2004) 947-970
13. Labrie F., Belanger A., Cusan L., and Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 82 (1997) 2403-2409
14. Labrie C., Belanger A., and Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 (1988) 1412-1417
15. Labrie F., Belanger A., Cusan L., Gomez J.-L., and Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82 (1997) 2396-2402
16. Labrie F., Belanger A., Belanger P., et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99 (2006) 182-188
17. Darling G.M., Johns J.A., McCloud P.I., and Davis S.R. Concurrent use of simvastatin and estrogen/progestin therapy compared with each therapy used alone for the treatment of hypercholesterolemia in postmenopausal women. Climacteric 2 (1999) I181-188
18. Baulieu E., Thomas G., Legrain S., et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue. Proc Nat Acad Natl Sci 97 (2000) 4279-4284
19. Bachmann G.A., Bancroft J., Braunstein G., et al. Female androgen insufficiency: The Princeton Consensus Statement on definition, classification and assessment. Fertil Steril 77 (2002) 665
20. Liu D., and Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha (i2,3). J Biol Chem 277 (2002) 21379-21388
21. Liu D., and Dillon J.S. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 69 (2004) 279-289
22. Labrie F., Belanger A., Belanger P., et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 103 (2007) 178-188
23. Nijland E., Davis S., Laan E., and Schultz W.W. Female sexual satisfaction and pharmaceutical intervention: a critical review of the drug intervention studies in female sexual dysfunction. J Sex Med 3 (2006) 763-777
24. Leiblum S., Koochaki P., Rodenberg C., Barton I., and Rosen R. Hypoactive sexual desire disorder in postmenopausal women: US results from the women's international study of health and sexuality (WISHeS). Menopause (New York, NY 13 (2006) 46-56
25. Biddle A.K., West S.L., D'Aloisio A.A., Wheeler S.B., Borisov N.N., and Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health (2009 Jan 12) [Epub ahead of print]
26. Dennerstein L., Randolph J., Taffe J., Dudley E., and Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 77 Suppl. 4 (2002) S42-S48
27. Avis N.E., Brockwell S., Randolph Jr. J.F., et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 16 (2009) 442-452
28. Nappi R.E., and Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 6 (2009) 603-616 [quiz 618-609]
29. Bachmann G.A., and Leiblum S.R. The impact of hormones on menopausal sexuality: a literature review. Menopause 11 (2004) 120-130
30. Alexander J.L., Kotz K., Dennerstein L., Kutner S.J., Wallen K., and Notelovitz M. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 11 (2004) 749-765
31. Modelska K., and Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 188 (2003) 286-293
32. Zumoff B., Strain G.W., Miller L.K., and Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 80 (1995) 1429-1430
33. Shifren J.L., Monz B.U., Russo P.A., Segreti A., and Johannes C.B. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 112 (2008) 970-978
34. Hayes R.D., Dennerstein L., Bennett C.M., Koochaki P.E., Leiblum S.R., and Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril 87 (2007) 107-112
35. Davis S.R., Davison S.L., Donath S., and Bell R.J. Circulating androgen levels and self-reported sexual function in women. JAMA 294 (2005) 91-96
36. Goldstat R., Briganti E., Tran J., Wolfe R., and Davis S. Transdermal testosterone improves mood, well being and sexual function in premenopausal women. Menopause (New York, NY) 10 (2003) 390-398
37. Shifren J.L., Braunstein G., Simon J., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med 343 (2000) 682
38. Braunstein G.D., Sundwall D.A., Katz M., et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165 (2005) 1582-1589
39. Davis S.R., van der Mooren M.J., van Lunsen R.H.W., et al. The efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause (New York, NY) 13 (2006) 387-396
40. Buster J.E., Kingsberg S.A., Aguirre O., et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105 (2005) 944
41. Davis S., Papalia M.A., Norman R.J., et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 148 (2008) 569-577
42. Mortola J.F., and Yen S.S. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 71 (1990) 696-704
43. Morales A.J., Nolan J.J., Nelson J.C., and Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age [erratum appears in J Clin Endocrinol Metab 1995;80(9):2799]. J Clin Endocrinol Metab 78 (1994) 1360-1367
44. Wolf O.T., Neumann O., Hellhammer D.H., et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 82 (1997) 2363-2367
45. Hackbert L., and Heiman J. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. J Womens Health Gend Based Med 11 (2002) 155
46. Schmidt P.J., Daly R.C., Bloch M., et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 62 (2005) 154
47. Donna K.-S. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and well-ness (DAWN) trial. J Am Geriat Soc 56 (2008) 1292-1298
48. Panjari M., Bell R.J., Jane F., et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 6 (2009) 2579-2590
49. Labrie F., Archer D., Bouchard C., et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause (New York, NY) 16 (2009) 907-922
50. Labrie F., Archer D., Bouchard C., et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause (New York, NY) 16 (2009) 923-931
51. Labrie F., Archer D., Bouchard C., et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause (New York, NY) 16 (2009) 897-906
52. Davis S.R. Androgen replacement in women: a commentary. J Clin Endocrinol Metab 84 6 (1999) 1886-1891
53. Oldenhave A., Jaszmann L.J., Haspels A.A., and Everaerd W.T. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 168 (1993) 772-780
54. Davis S.R., Moreau M., Kroll R., et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 359 (2008) 2005-2017
55. Bloch M., Schmidt P.J., Danaceau M.A., Adams L.F., and Rubinow D.R. Dehydroepiandrosterone treatment of midlife dysthymia [see comment]. Biol Psychiatry 45 (1999) 1533-1541
56. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355 (2006) 1647-1659
57. Wu F.C.W., and von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 24 (2003) 183-217
58. Williams J.R. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids 35 (2000) 325-331
59. Cheng H.H., Hu X.J., and Ruan Q.R. Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen. Acta Pharmacol Sin (2008)
60. Barrett-Connor E., Khaw K.T., and Yen S.S. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Eng J Med 315 (1986) 1519-1524
61. Barrett-Connor E., and Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 91 (1995) 1757
62. Somboonporn W., Davis S., Seif M., and Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev (2009) [CD004509]
63. Barrett-Connor E., Slone S., Greendale G., et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 27 (1997) 261-274
64. Floter A., Nathorst-Boos J., Carlstrom K., and von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. Maturitas 47 (2004) 123-129
65. Leao L.M., Duarte M.P., Silva D.M., Bahia P.R., Coeli C.M., and de Farias M.L. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur J Endocrinol 154 (2006) 131-139
66. Davis S.R., Goldstat R., Newman A., et al. Differing effects of low dose estrogen and progestin replacement therapy and pravastatin in hypercholesterolemic postmenopausal women. Climacteric 5 (2002) 341-360
67. Labrie F., Diamond P., Cusan L., Gomez J.L., Belanger A., and Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 82 (1997) 3498-3505
68. Casson P.R., Santoro N., Elkind-Hirsch K., et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril 70 (1998) 107
69. Srinivasan M., Irving B.A., Dhatariya K., et al. Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. J Clin Endocrinol Metab 94 (2009) 761-764
70. Barnhart K.T., Freeman E., Grisso J.A., et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 84 (1999) 3896-3902
71. Johannsson G., Burman P., Wiren L., et al. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab 87 (2002) 2046
72. Dhatariya K., Bigelow M.L., and Nair K.S. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54 (2005) 765-769
73. Dayal M., Sammel M.D., Zhao J., Hummel A.C., Vandenbourne K., and Barnhart K.T. Supplementation with DHEA: effect on muscle size, strength, quality of life, and lipids. Journal of Women's Health 14 (2005) 391-400
74. Morales A.J., Haubrich R.H., Hwang J.Y., Asakura H., and Yen S.S. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 49 (1998) 421-432
75. Arlt W., Callies F., Van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med 341 (1999) 1013
76. Allolio B., Callies F., and Arlt W. Dehydroepiandrosterone substitution in women. J Endocrinol Invest 22 (1999) 29-31
77. Lovas K., Gebre-Medhin G., Trovik T.S., et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized parallel group clinical trial. J Clin Endocrinol Metab 88 (2003) 1112
78. Villareal D., Holloszy J., and Kohrt W. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 53 (2000) 561-568
79. Igwebuike A., Irving B.A., Bigelow M.L., Short K.R., McConnell J.P., and Nair K.S. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab 93 (2008) 534-538
80. van Thiel S.W., Romijn J.A., Pereira A.M., et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab 90 (2005) 3295-3303
81. Panjari M., Bell R.J., Jane F., Adams J., Morrow C., and Davis S.R. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 63 (2009) 240-245
82. Livingstone C., and Collison M. Sex steroids and insulin resistance. Clin Sci (Lond) 102 (2002) 151-166
83. Wellman M., Shane-McWhorter L., Orlando, and Jennings J.P. The role of dehydroepiandrosterone in diabetes mellitus. Pharmacotherapy 19 (1999) 582-591
84. Lasco A., Frisina N., Morabito N., et al. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol 145 (2001) 457-461
85. Villareal D.T., and Holloszy J.O. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 292 (2004) 2243
86. Gebre-Medhin G., Husebye E.S., Mallmin H., et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol 52 (2000) 775-780
87. Callies F., Fassnacht M., van Vlijmen J.C., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. J Clin Endocrinol Metab 86 (2001) 1968-1972
88. Panjari M., and Davis S.R. DHEA therapy for women: effect on sexual function and wellbeing. Human Reprod Update 13 (2007) 239-248
89. Hunt P., Gurnell E., and Huppert F. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 85 (2000) 4650-4656
90. Lovas K., Gebre-Medhin G., Trovik T., et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month randomized parallel group clinical trial. J Clin Endocrinol Metab 88 (2003) 1112-1118
91. Alkatib A.A., Cosma M., Elamin M.B., et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 94 (2009) 3676-3681
92. Genazzani A.D., Stomati M., Bernardi F., Pieri M., Rovati L., and Genazzani A.R. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. Fertil Steril 80 (2003) 1495-1501
93. Stomati M., Monteleone P., Casarosa E., et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol Endocrinol 14 (2000) 342-363
94. Pluchino N., Ninni F., Stomati M., et al. One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women, effects on hormonal milieu. Maturitas 59 (2008) 293-303
95. Diamond P., Cusan L., Gomez J.L., Belanger A., and Labrie F. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol 150 Suppl (1996) S43-S50